by The global cardiac resynchronization therapy market size was valued at USD 4.85 billion in 2020, and is predicted to be worth around USD 10.8 billion by 2030, registering a CAGR of 7.2% during the forecast period 2022 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39116
Table of Contents
Cardiac Resynchronization Therapy Market Growth Factors
The key factors driving the market include constant product advancements, growing initiatives by key companies, and increasing product adoption by end-users. The market was significantly impacted by the COVID-19 pandemic. Some of the major impacts of the pandemic on the market include supply chain disruptions, fall in sales, demand slowdown due to cancellation of elective procedures, and operational hurdles. For instance, Abbott, a market leader in the cardiac rhythm management device industry, reported a decline in revenue growth of the cardiovascular business in 2020.
Growing product developments, aging population, initiatives by key companies, and prevalence of Cardiovascular Diseases (CVDs) are some of the key drivers of this market.
Several key companies, such as Medtronic, Boston Scientific, and Microport, reported a negative impact of COVID-19 on their financial performance and business activities. Microport, for instance, reported a 16.2% decline in its cardiac rhythm management business in 2020.
Cardiac Resynchronization Therapy Market Report Coverage
| Report Scope | Details |
| Market Size | US$ 10.8 billion by 2030 |
| Growth Rate | CAGR of 7.2% From 2022 to 2030 |
| Largest Market | North America |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product, End-user |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Medtronic; Abbott; Boston Scientific Corp.; Biotronik SE & Co. KG; MicroPort Scientific Corp. |
By End-user Analysis
On the basis of end-users, the global market has been divided into hospitals, cardiac centers, and others. The hospital end-user segment accounted for the largest revenue share of the global market of more than 52% in 2021.
The cardiac center end-user segment is anticipated to register the fastest growth rate over the forecast period on account of a rise in the number of cardiac specialty centers and the growing prevalence of cardiovascular diseases across the globe.
By Product Analysis
On the basis of products, the global market has been bifurcated into CRT-defibrillators and CRT-pacemakers. The CRT-defibrillators product segment accounted for the largest share of more than 58% of the global revenue in 2021.
The CRT-pacemakers segment, on the other hand, is expected to grow at the fastest CAGR during the forecast period. This is owing to the increasing geriatric population across the globe, the prevalence of cardiac conditions, and product advancements by key market players.
By Regional Analysis
North America accounted for the maximum revenue share of more than 39% in 2021. The large share of the region is due to the increasing geriatric population and growing regulatory approvals.
This is owing to rapidly developing healthcare infrastructure, growing aging population, improvement in economic conditions, strategic initiatives by key companies, and growing prevalence of cardiac diseases.
MicroPort, for example, is a Chinese company specializing in a variety of medical devices, including CRT-Ds and CRT-Ps. The company is a domestic leader in the cardiac rhythm management market.
Read also @ Small Molecule innovator CDMO Market Size Hit US$ 73.9 billion by 2030
Major Key Players Covered in The Cardiac Resynchronization Therapy Market Report include
- Medtronic
- Abbott
- Boston Scientific Corp.
- Biotronik SE & Co., KG
- MicroPort Scientific Corp.
Cardiac Resynchronization Therapy Market Segmentation
- By Product
- CRT-Defibrillator
- CRT-Pacemaker
- By End-user
- Hospital
- Cardiac Center
- Others
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Cardiac Resynchronization Therapy Market, By Product
7.1. Cardiac Resynchronization Therapy Market, by Product, 2021-2030
7.1.1. CRT-Defibrillator
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. CRT-Pacemaker
7.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Cardiac Resynchronization Therapy Market, By End-user
8.1. Cardiac Resynchronization Therapy Market, by End-user, 2021-2030
8.1.1. Hospital
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Cardiac Center
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Cardiac Resynchronization Therapy Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Product (2019-2030)
9.1.2. Market Revenue and Forecast, by End-user (2019-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Product (2019-2030)
9.1.3.2. Market Revenue and Forecast, by End-user (2019-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Product (2019-2030)
9.1.4.2. Market Revenue and Forecast, by End-user (2019-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Product (2019-2030)
9.2.2. Market Revenue and Forecast, by End-user (2019-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Product (2019-2030)
9.2.3.2. Market Revenue and Forecast, by End-user (2019-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Product (2019-2030)
9.2.4.2. Market Revenue and Forecast, by End-user (2019-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
9.2.5.2. Market Revenue and Forecast, by End-user (2019-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
9.2.6.2. Market Revenue and Forecast, by End-user (2019-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Product (2019-2030)
9.3.2. Market Revenue and Forecast, by End-user (2019-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Product (2019-2030)
9.3.3.2. Market Revenue and Forecast, by End-user (2019-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Product (2019-2030)
9.3.4.2. Market Revenue and Forecast, by End-user (2019-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
9.3.5.2. Market Revenue and Forecast, by End-user (2019-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
9.3.6.2. Market Revenue and Forecast, by End-user (2019-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Product (2019-2030)
9.4.2. Market Revenue and Forecast, by End-user (2019-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Product (2019-2030)
9.4.3.2. Market Revenue and Forecast, by End-user (2019-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Product (2019-2030)
9.4.4.2. Market Revenue and Forecast, by End-user (2019-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
9.4.5.2. Market Revenue and Forecast, by End-user (2019-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
9.4.6.2. Market Revenue and Forecast, by End-user (2019-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Product (2019-2030)
9.5.2. Market Revenue and Forecast, by End-user (2019-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Product (2019-2030)
9.5.3.2. Market Revenue and Forecast, by End-user (2019-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Product (2019-2030)
9.5.4.2. Market Revenue and Forecast, by End-user (2019-2030)
Chapter 10. Company Profiles
10.1. Medtronic
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Abbott
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Boston Scientific Corp.
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Biotronik SE & Co., KG
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. MicroPort Scientific Corp
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39116
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
